Head-to-head · Cost-Efficiency Index
Peter MD vs Aspen
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Peter MD
Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Visit Peter MDAspen
Cost-first shoppers who want wanting one flat price regardless of whether treatment ends up being semaglutide or tirzepatide, if willing to commit to 3 months.
Visit AspenThe verdict
Aspen takes it, leading the Cost-Efficiency Index 74 to 72. Aspen Health (startaspen.com) is a cash-pay telehealth platform spanning weight loss, hair health, longevity, and sexual wellness. Peter MD still earns a C — Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Aspen.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Peter MD | Aspen |
|---|---|---|
| Cost-Efficiency Index | 72/100 | 74/100 |
| Semaglutide / mo | $149/mo first-time (Level 1), $139/mo returning (Level 2) | $179/mo (all doses, compounded) |
| Tirzepatide / mo | $149 first month, then $249/mo billed quarterly | $179/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $2,148 |
| Tirzepatide / yr (modeled) | $2,988 | $2,148 |
| Coverage | Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider) | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #54 | #57 |
Peter MD
72/100Where the value is
- Broadest cross-category catalog in this ranking under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalog as the GLP-1 line for anyone consolidating multiple scripts
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
Aspen
74/100Where the value is
- One transparent, dose-independent flat price ($179/mo) covers either the semaglutide or tirzepatide path, avoiding the tirzepatide surcharge most compounded competitors charge
- Price stated to be all-in: provider consultation, custom dosing, medication, and free delivery bundled with no listed add-on fees
- No insurance required, cash-pay simplicity
The tradeoffs
- The bold '$179/mo' headline omits its own fine-print condition — a 3-month commitment — visible only in small text directly beneath the price
- Almost nothing else is disclosed on the public site: no states-served list, no named medical director or prescriber, no named pharmacy, and no LegitScript certification found
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.